TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36600424

Group type: EXPERIMENTAL
Intervention: Active immunotherapy with anakinra (recombinant interleukin-1 receptor antagonist) intravenously for patients with MALS
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Active immunotherapy with subcutaneous recombinant human interferon-gamma for patients with immunoparalysis
Number of subjects: 280

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 280
Study: 36600427

Group type: EXPERIMENTAL
Intervention: HCL-LCD (Hybrid Closed Loop system with Low Carbohydrate Diet, <130 g carbohydrate/day) for >8 months
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard diabetes care with intermittent blinded CGM (non-HCL)
Number of subjects: 24
Study: 36600428

Group type: EXPERIMENTAL
Intervention: Community Engagement (CE) activities in intervention clusters
Number of subjects: 39362

Group type: COMPARATOR
Intervention: Control group (no CE activities)
Number of subjects: 39362
Study: 36600432

Group type: EXPERIMENTAL
Intervention: Neurological Pupillary Index (NPi) during cardiopulmonary resuscitation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neurological Pupillary Index (NPi)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glasgow Coma Scale (GCS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modified Rankin Score
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biomarkers and neurophysiology exams
Number of subjects: 0
Study: 36600534

Group type: EXPERIMENTAL
Intervention: Adjuvant chemoradiation followed by olaparib for 2 years
Number of subjects: 1470

Group type: COMPARATOR
Intervention: Adjuvant chemoradiation alone
Number of subjects: 1470

Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy with concurrent and adjuvant durvalumab for 1 year
Number of subjects: 1470

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 1470

Group type: EXPERIMENTAL
Intervention: Radiotherapy followed by progestin for 2 years
Number of subjects: 1470

Group type: COMPARATOR
Intervention: Adjuvant chemoradiation
Number of subjects: 1470
Study: 36600535

Group type: EXPERIMENTAL
Intervention: Acupuncture alone (group A)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Acupuncture with additional manual-movement and mind-body therapies (group B)
Number of subjects: 120
Study: 36600561

Group type: EXPERIMENTAL
Intervention: Mupadolimab (anti-CD73 antibody)
Number of subjects: 0
Study: 36600670

Group type: EXPERIMENTAL
Intervention: Ponatinib 45 mg daily for 14 days during induction, then 45 mg daily continuously or 30 mg daily continuously with dose reduction to 15 mg daily upon achieving complete molecular response (CMR). Maintenance therapy included daily ponatinib and vincristine-prednisone monthly for 2 years, followed by daily ponatinib indefinitely. Intrathecal injections of cytarabine and methotrexate for CNS prophylaxis.
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Ponatinib-related deaths from myocardial infarction in the first 37 patients treated.
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Adverse events related to ponatinib and hyper-CVAD treatment.
Number of subjects: 86
Study: 36601090

Group type: EXPERIMENTAL
Intervention: tofacitinib
Number of subjects: 0
Study: 36601119

Group type: EXPERIMENTAL
Intervention: CLIC-1901 (non-cryopreserved CAR-T cells)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lymphodepletion with fludarabine and cyclophosphamide prior to CAR-T infusion
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: CLIC-1901 dose infused
Number of subjects: 30
Study: 36601286

Group type: EXPERIMENTAL
Intervention: Young Person's Face IT (YPF), an online intervention based on cognitive behavioural therapy and social skills training.
Number of subjects: 0
Study: 36601889

Group type: EXPERIMENTAL
Intervention: Sodium intake
Number of subjects: 800
Study: 36601916

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) at levels of 4, 8, 12, and 16 cm H2O
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 0
Study: 36601956

Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan administered twice daily for 52 weeks
Number of subjects: 375

Group type: COMPARATOR
Intervention: Enalapril administered twice daily for 52 weeks
Number of subjects: 375
Study: 36601972

Group type: EXPERIMENTAL
Intervention: Cabozantinib 60 mg/day
Number of subjects: 34
Study: 36602226

Group type: EXPERIMENTAL
Intervention: Combination of pyrotinib, letrozole, and dalpiciclib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dalpiciclib
Number of subjects: 0
Study: 36602324

Group type: EXPERIMENTAL
Intervention: Osteoarthritis Symptom Inventory Scale (OASIS9)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: OASIS9 psychometric properties
Number of subjects: 123
Study: 36602619

Group type: EXPERIMENTAL
Intervention: Automated online behavioral weight loss program
Number of subjects: 63
Study: 36602718

Group type: EXPERIMENTAL
Intervention: Topical DEX (dexamethasone)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Topical DICLO (diclofenac)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Topical DEX + DICLO (dexamethasone and diclofenac)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Topical DEX
Number of subjects: 69

Group type: COMPARATOR
Intervention: Topical DICLO
Number of subjects: 69

Group type: COMPARATOR
Intervention: Topical DEX + DICLO
Number of subjects: 69
Study: 36602748

Group type: EXPERIMENTAL
Intervention: Lenvatinib
Number of subjects: 703
Study: 36602796

Group type: COMPARATOR
Intervention: gemcitabine (1000 mg/m2) and nab-paclitaxel (125 mg/m2)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: gemcitabine (1000 mg/m2) and nab-paclitaxel (125 mg/m2) and NPC-1C (1.5 mg/kg every 2 weeks)
Number of subjects: 78
Study: 36602803

Group type: EXPERIMENTAL
Intervention: Intensive Outpatient Program PE (IOP-PE)
Number of subjects: 234

Group type: COMPARATOR
Intervention: Massed-PE
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 234
Study: 36602841

Group type: EXPERIMENTAL
Intervention: JITAI-MRFCBT
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control
Number of subjects: 20
Study: 36602846

Group type: EXPERIMENTAL
Intervention: Relapse prevention treatment
Number of subjects: 160

Group type: COMPARATOR
Intervention: Treatment as usual (control)
Number of subjects: 160
Study: 36602852

Group type: EXPERIMENTAL
Intervention: PTSD Family Coach 1.0
Number of subjects: 200
Study: 36602868

Group type: EXPERIMENTAL
Intervention: Evolocumab
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 36602883

Group type: EXPERIMENTAL
Intervention: R-One robotic PCI system
Number of subjects: 62
Study: 36602886

Group type: COMPARATOR
Intervention: Dance
Number of subjects: 7939

Group type: COMPARATOR
Intervention: Aqua-based training
Number of subjects: 7939

Group type: COMPARATOR
Intervention: Gait/balance/functional training
Number of subjects: 7939

Group type: COMPARATOR
Intervention: Multi-domain training
Number of subjects: 7939

Group type: COMPARATOR
Intervention: Mind-body training
Number of subjects: 7939

Group type: COMPARATOR
Intervention: Endurance training
Number of subjects: 7939

Group type: COMPARATOR
Intervention: Flexibility training
Number of subjects: 7939

Group type: COMPARATOR
Intervention: Strength/resistance training
Number of subjects: 7939

Group type: COMPARATOR
Intervention: LSVT BIG
Number of subjects: 7939
Study: 36602914

Group type: EXPERIMENTAL
Intervention: Mindfulness, safety, and health program (self-administered, 30-minute sessions once a week for 12 weeks, using web-based learning modules and the Headspace app)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Mindfulness, safety, and health program
Number of subjects: 100
Study: 36602927

Group type: EXPERIMENTAL
Intervention: Second-generation atypical antipsychotics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antidepressants
Number of subjects: 0
Study: 36602998

Group type: EXPERIMENTAL
Intervention: Motion Sickness Severity Scale (MSSS)
Number of subjects: 63
Study: 36603136

Group type: EXPERIMENTAL
Intervention: Mobile App-based Coping Skills Training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 36603135

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 36603167

Group type: EXPERIMENTAL
Intervention: Economic empowerment intervention, details not available
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group, details not available
Number of subjects: 0
Study: 36603175

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with gemcitabine and split-dose cisplatin (GC)
Number of subjects: 57
Study: 36603187

Group type: EXPERIMENTAL
Intervention: Cranial radiation therapy (CRT) delivered to 90.8% of participants in AALL0434
Number of subjects: 2164

Group type: EXPERIMENTAL
Intervention: Intensified chemotherapy without CRT in AALL1231, delivered to 88.2% of participants
Number of subjects: 2164

Group type: EXPERIMENTAL
Intervention: Nelarabine on AALL0434
Number of subjects: 2164

Group type: COMPARATOR
Intervention: CNS-3 status with CRT
Number of subjects: 2164

Group type: COMPARATOR
Intervention: CNS-1 and CNS-2 status at diagnosis
Number of subjects: 2164
Study: 36603202

Group type: EXPERIMENTAL
Intervention: Immediate pushing
Number of subjects: 941

Group type: COMPARATOR
Intervention: Delayed pushing
Number of subjects: 941
Study: 36603216

Group type: EXPERIMENTAL
Intervention: Phase-dependent electrical stimulation of afferent pathways
Number of subjects: 0
Study: 36603460

Group type: EXPERIMENTAL
Intervention: Individualized nutritional support
Number of subjects: 573

Group type: COMPARATOR
Intervention: Usual care nutrition
Number of subjects: 573
Study: 36603478

Group type: EXPERIMENTAL
Intervention: CTA analyzed using ElucidVivo (Elucid Bioimaging Inc.)
Number of subjects: 576

Group type: EXPERIMENTAL
Intervention: Histopathologic correlates
Number of subjects: 576
Study: 36603566

Group type: EXPERIMENTAL
Intervention: Tofacitinib
Number of subjects: 1073

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1073
Study: 36603963

Group type: EXPERIMENTAL
Intervention: Reformer pilates exercises (2 times a week for 6 weeks)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Home mat pilates exercises (2 times a week for 6 weeks)
Number of subjects: 28
Study: 36604128

Group type: EXPERIMENTAL
Intervention: Cloth mask
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Surgical mask
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: FFP3 mask
Number of subjects: 72

Group type: COMPARATOR
Intervention: No mask
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Face mask wearing during exercise
Number of subjects: 72
Study: 36604127

Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel and cisplatin administered via pressurised intraperitoneal aerosol chemotherapy (PIPAC)
Number of subjects: 0
Study: 36604153

Group type: EXPERIMENTAL
Intervention: tofacitinib
Number of subjects: 0
Study: 36604156

Group type: EXPERIMENTAL
Intervention: AUTO BFR training
Number of subjects: 56

Group type: COMPARATOR
Intervention: NAUTO BFR training
Number of subjects: 56
Study: 36604240

Group type: EXPERIMENTAL
Intervention: Weight loss clinical trial
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Physical activity and healthy food choices
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Meeting U.S. guidelines for MVPA and FVI
Number of subjects: 110
Study: 36604262

Group type: EXPERIMENTAL
Intervention: Vitamin D 60,000 IU monthly
Number of subjects: 5670

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5670
Study: 36604372

Group type: EXPERIMENTAL
Intervention: Backward walking ability evaluated with the 3-Meter Back Walk Test (3MBWT)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Trunk Control Measurement Scale (TCMS)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Gillette Functional Assessment Questionnaire (FAQ)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 3MBWT
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Hip extension proprioception
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: FAQ
Number of subjects: 30
Study: 36604685

Group type: EXPERIMENTAL
Intervention: Thinking Healthy Programme - Brief Group version (THP-BGV) delivered in five online sessions by antenatal nurses.
Number of subjects: 88

Group type: COMPARATOR
Intervention: Usual care consisting of routine online educational pregnancy classes aided by antenatal nurses.
Number of subjects: 88
Study: 36604714

Group type: EXPERIMENTAL
Intervention: Self-directed learning (online access to program materials)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Facilitated learning (includes live webinars)
Number of subjects: 0
Study: 36604756

Group type: EXPERIMENTAL
Intervention: Intravitreal sirolimus and adjunct aflibercept (combination)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Aflibercept monotherapy (control)
Number of subjects: 20
Study: 36605275

Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 0
Study: 36605436

Group type: EXPERIMENTAL
Intervention: Avelumab (PD-L1 antibody) combined with FOLFOX chemotherapy and cetuximab (anti-EGFR antibody)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Avelumab, FOLFOX, and cetuximab
Number of subjects: 43
Study: 36606005

Group type: EXPERIMENTAL
Intervention: Low-intensity psychosocial telemental maternal intervention
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 58
Study: 36606032

Group type: EXPERIMENTAL
Intervention: Digital therapeutic intervention (DTxP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 36606049

Group type: EXPERIMENTAL
Intervention: PET/CT at baseline and month 3 (M3)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Conventional imaging
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Baseline PET/CT
Number of subjects: 52
Study: 36606059

Group type: EXPERIMENTAL
Intervention: EQ-5D full health state (FHS) after therapeutic intervention
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Experience of EQ-5D-3L FHS and 'no problems' in mobility after therapeutic intervention
Number of subjects: 147

Group type: COMPARATOR
Intervention: No FHS respondents
Number of subjects: 147
Study: 36606100

Group type: EXPERIMENTAL
Intervention: DAA regimen (direct-acting antiviral treatment); 8 patients started treatment
Number of subjects: 12500

Group type: EXPERIMENTAL
Intervention: Patient education
Number of subjects: 12500

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 12500
Study: 36606131

Group type: EXPERIMENTAL
Intervention: Comprehensive anti-stigma intervention
Number of subjects: 0
Study: 36606308

Group type: EXPERIMENTAL
Intervention: Consistent mask wearing
Number of subjects: 3903

Group type: EXPERIMENTAL
Intervention: Unvaccinated individuals
Number of subjects: 3903

Group type: EXPERIMENTAL
Intervention: Not wearing a mask
Number of subjects: 3903

Group type: EXPERIMENTAL
Intervention: Unvaccinated and not wearing a mask
Number of subjects: 3903

Group type: COMPARATOR
Intervention: Always wearing a mask and vaccinated (≥14 days after mRNA vaccination)
Number of subjects: 3903
Study: 36606536

Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg administered subcutaneously for 52 weeks
Number of subjects: 160

Group type: COMPARATOR
Intervention: Narrow-band ultraviolet B (nb-UVB) phototherapy
Number of subjects: 160
Study: 36606571

Group type: EXPERIMENTAL
Intervention: CH-EUS MASTER guided EUS-FNA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (EUS-FNA without CH-EUS MASTER guidance)
Number of subjects: 0
Study: 36606664

Group type: EXPERIMENTAL
Intervention: FOLFOX (5-fluorouracil, leucovorin, oxaliplatin)
Number of subjects: 0
Study: 36606801

Group type: EXPERIMENTAL
Intervention: Subjective mental health rating
Number of subjects: 850

Group type: EXPERIMENTAL
Intervention: Subjective physical health rating
Number of subjects: 850

Group type: EXPERIMENTAL
Intervention: EQ-5D Visual Analog Scale
Number of subjects: 850

Group type: EXPERIMENTAL
Intervention: Stepwise regression with additional covariates
Number of subjects: 850
Study: 36607429

Group type: EXPERIMENTAL
Intervention: Zolbetuximab alone (n=5)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Zolbetuximab + Zoledronic Acid (ZA) + Intermediate-dose IL-2 (3 mIU) (n=7)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Zolbetuximab + Zoledronic Acid (ZA) + Low-dose IL-2 (1 mIU) (n=9)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Zolbetuximab + Zoledronic Acid (ZA) + IL-2 (both doses)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Clinical efficacy population (n=19)
Number of subjects: 28
Study: 36607533

Group type: EXPERIMENTAL
Intervention: High-frequency percussive ventilation (HFPV) for 10 minutes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-frequency percussive ventilation (HFPV)
Number of subjects: 0
Study: 36607544

Group type: EXPERIMENTAL
Intervention: CMAB008 (an Infliximab Biosimilar)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Remicade
Number of subjects: 0
Study: 36607707

Group type: EXPERIMENTAL
Intervention: Know@Home mobile app
Number of subjects: 2093

Group type: COMPARATOR
Intervention: Referral to web resources
Number of subjects: 2093

Group type: EXPERIMENTAL
Intervention: HIV self-tests (HIVSTs) provided to all participants
Number of subjects: 2093

Group type: EXPERIMENTAL
Intervention: Mobile app
Number of subjects: 2093
Study: 36607735

Group type: EXPERIMENTAL
Intervention: PVX2 vaccination (twice with HPV16-targeting pNGVL4a-Sig/E7(detox)/HSP70 plasmid and once with TA-CIN protein)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: PVX2 vaccination
Number of subjects: 12
Study: 36607832

Group type: EXPERIMENTAL
Intervention: Low EQ-5D index
Number of subjects: 2205

Group type: EXPERIMENTAL
Intervention: Low VAS score
Number of subjects: 2205
Study: 36607849

Group type: EXPERIMENTAL
Intervention: Low bone mineral density (BMD)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal bone mineral density (BMD)
Number of subjects: 40
Study: 36607971

Group type: EXPERIMENTAL
Intervention: Post-acute care (PAC) with comprehensive geriatric assessment (CGA), exercise, nutrition education, and medicinal adjustments for two to four weeks
Number of subjects: 254

Group type: COMPARATOR
Intervention: Control group receiving only comprehensive geriatric assessment (CGA)
Number of subjects: 254
Study: 36608001

Group type: EXPERIMENTAL
Intervention: Combat Application Tourniquet (CAT) applied to each thigh, tightened until no pulse is felt in the lower extremity.
Number of subjects: 0
Study: 36608033

Group type: EXPERIMENTAL
Intervention: Fluorescence lifetime imaging ophthalmoscopy (FLIO) with 473 nm laser excitation
Number of subjects: 141
Study: 36608305

Group type: EXPERIMENTAL
Intervention: Lenvatinib and Pembrolizumab
Number of subjects: 0
Study: 36608308

Group type: EXPERIMENTAL
Intervention: GEN-1 (neoadjuvant single-arm phase IB study)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Standard neoadjuvant chemotherapy (historical control arm)
Number of subjects: 18
Study: 36608310

Group type: EXPERIMENTAL
Intervention: ibrutinib 420 mg once daily plus prednisone (1 mg/kg once daily)
Number of subjects: 193

Group type: COMPARATOR
Intervention: placebo plus prednisone
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: ibrutinib-prednisone
Number of subjects: 193

Group type: COMPARATOR
Intervention: placebo-prednisone
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: ibrutinib treatment
Number of subjects: 193
Study: 36608320

Group type: EXPERIMENTAL
Intervention: Encorafenib 450 mg once daily and binimetinib 45 mg twice daily
Number of subjects: 12
Study: 36608383

Group type: EXPERIMENTAL
Intervention: Interval cytoreductive surgery (ICS) followed by hyperthermic intraperitoneal chemotherapy (HIPEC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Interval cytoreductive surgery (ICS)
Number of subjects: 0
Study: 36608382

Group type: EXPERIMENTAL
Intervention: Diet plus physical activity intervention delivered via centralized telephone-based health coaching
Number of subjects: 1205

Group type: COMPARATOR
Intervention: Control condition (not specified)
Number of subjects: 1205
Study: 36608413

Group type: EXPERIMENTAL
Intervention: Reflexology
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Sucrose (24% solution)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Kangaroo care
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Classical music
Number of subjects: 300

Group type: COMPARATOR
Intervention: Nonpharmacologic methods (including reflexology, sucrose, kangaroo care, classical music)
Number of subjects: 300
Study: 36608435

Group type: EXPERIMENTAL
Intervention: SAPIEN 3 Transcatheter Heart Valve (THV) implantation
Number of subjects: 58
Study: 36608483

Group type: EXPERIMENTAL
Intervention: MDD-PRS (Polygenic Risk Score for Major Depressive Disorder)
Number of subjects: 443
Study: 36608945

Group type: EXPERIMENTAL
Intervention: Community gardening intervention (receiving a community garden plot)
Number of subjects: 291

Group type: COMPARATOR
Intervention: Control group (remained on waiting list and did not garden)
Number of subjects: 291
Study: 36609028

Group type: COMPARATOR
Intervention: ADHD diagnosis
Number of subjects: 6993

Group type: COMPARATOR
Intervention: ADHD symptoms
Number of subjects: 6993

Group type: COMPARATOR
Intervention: Control (absence of ADHD)
Number of subjects: 6993
Study: 36609038

Group type: EXPERIMENTAL
Intervention: DCB-based treatment
Number of subjects: 254

Group type: COMPARATOR
Intervention: DES-only treatment
Number of subjects: 254
Study: 36609046

Group type: EXPERIMENTAL
Intervention: Transdermal Glyceryl Trinitrate Patches
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 36609057

Group type: EXPERIMENTAL
Intervention: Heart Rate (HR)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Surgical Pleth Index (SPI)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Pupillary Pain Index (PPI)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Nociception Level (NOL)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Multivariable predictor combining NOL with ASA physical status and regional anaesthesia use
Number of subjects: 60
Study: 36609101

Group type: EXPERIMENTAL
Intervention: Super high-pressure balloon
Number of subjects: 80

Group type: COMPARATOR
Intervention: Intravascular lithotripsy (IVL)
Number of subjects: 80
Study: 36609226

Group type: EXPERIMENTAL
Intervention: General Anesthesia Group (GAG, n=18)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Regional Anesthesia Group (RAG, n=28)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Both groups (GAG and RAG)
Number of subjects: 46
Study: 36609248

Group type: EXPERIMENTAL
Intervention: Patient Navigation Intervention
Number of subjects: 24281